The aim of the study was to evaluate the efficacy and tolerability of the drug Molnupiravir in
adult outpatients with mild Covid–19. Materials and methods. A randomized comparative …

The COVID-19 pandemic is still an unresolved global health concern, although half of the
world's population has been vaccinated. The pharmaceutical industries are still struggling to …

Background: Molnupiravir is a ribonucleoside analog and exhibits its antiviral mechanism by
inhibiting replication. Preclinical studies have been reported that support the role of …

Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …

The key goal of this mini review article is to provide enough data and info on the several
clinical trials conducted in some number of countries in the Asia on the use of the drug …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Objectives: Below we report our experience in the use of molnupiravir, the first antiviral drug
against SARS-CoV-2 available to us, in the treatment of patients with COVID-19. Materials …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Introduction Molnupiravir is an orally available prodrug of N-hydroxycytidine that received
special approval for emergency treatment of coronavirus disease 2019 (COVID-19) in Japan …